The Pfizer laboratory announced that a clinical trial on its anti-COVID pill – the first of its kind – showed high effectiveness.
The drug called Paxlovid managed to lower the risk of hospitalization and death by 89% among adult COVID-19 patients at high risk of developing severe forms of the disease, Pfizer said.
The results of this interim clinical trial are so good that the US lab said it will stop recruiting new people for the trial.
He added that he will send the data to the Food and Drug Administration (FDA) as soon as possible as part of his “continuous presentation”To obtain authorization for emergency use.
“Today’s news is a real game changer in global efforts to halt the devastation of this pandemic.”Said the CEO of Pfizer, Albert Bourla.
“These data suggest that our oral antiviral candidate, if approved or licensed by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of 10 hospitalizations.”He added.
The main analysis of the trial evaluated data from 1,219 adults in North and South America, Europe, Africa, and Asia.
Several laboratories are working on oral antivirals that would mimic the influenza drug Tamiflu and prevent the disease from progressing to serious stages.
Pfizer began developing its anti-COVID drug in March 2020, the first specifically designed against the coronavirus.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
